Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial
Sign Up to like & getrecommendations! Published in 2022 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/ard-2022-222405
Abstract: Objectives To characterise infections in patients with rheumatoid arthritis (RA) in ORAL Surveillance. Methods In this open-label, randomised controlled trial, patients with RA aged≥50 years with ≥1 additional cardiovascular risk factor received tofacitinib 5 or… read more here.
Keywords: two times; versus tnfi; per day; times per ... See more keywords
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study
Sign Up to like & getrecommendations! Published in 2024 at "RMD Open"
DOI: 10.1136/rmdopen-2023-003912
Abstract: Objectives Compare the risk of extended major adverse cardiovascular (CV) event (MACE) composite outcomes and component events in patients with rheumatoid arthritis (RA) treated with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in Oral Rheumatoid… read more here.
Keywords: versus tnfi; mace; tofacitinib versus; risk ... See more keywords